Drug-coated balloon catheter

Abstract

The invention relates to a drug-coated balloon catheter. The drug-coated balloon catheter comprises a balloon and a drug coating on the surface of the balloon. The drug coating comprises an active drug and a carrier. The active drug is paclitaxel, rapamycin, a paclitaxel derivative or a rapamycin derivative. The carrier comprises an organic acid salt and polyol. A mass ratio of the active drug to the carrier in the drug coating is 0.5-49. A mass ratio of the organic acid salt to polyol is (3-50): 1. The organic acid salt and polyol in the drug coating produce synergism, drug particles have small particle sizes, premature release of the drug before displacement of the balloon catheter to a target point is prevented, balloon surface drug fast release is promoted, drug absorption by target tissue is promoted, a drug loss is reduced in a conveying process, particle falling is reduced, coating safety is improved and good drug transshipment effects are obtained.

Description

technical field [0001] The invention belongs to the field of interventional medical devices, in particular to a drug-coated balloon catheter. Background technique [0002] From the 1970s to the present, the field of cardiovascular interventional therapy has experienced three milestone leaps. In 1977, the human first used balloon to dilate coronary artery stenosis, which was the first milestone. Although balloon dilatation can eliminate coronary artery stenosis, the elastic recoil of the vessel wall, hyperplasia of the intimal layer, and tearing of the intimal wall can promote restenosis of the vessel, and restenosis of the target vessel occurs 3 to 6 months after surgery. The rate is as high as 30-50%. In 1986, the bare metal stent (abbreviation: BMS) came out. It can not only eliminate the immediate vascular stenosis, but also greatly reduce the incidence of acute reocclusion. It has become the second milestone in interventional therapy, but the incidence of target vessel...

AI Technical Summary

Problems solved by technology

[0003] The invention of the stent provides a better solution for atherosclerosis and intravascular stenosis, which greatly improves the treatment efficiency, but at the same time, intravascular and intrastent restenosis occurs. For small vessels, bifurcated vessels and in situ Due to the unsatisfactory treatment effect of lesions and other shortcomings, the absolute number of patients with stent restenosis is considerable due to the increase in the number of patients receiving PCI treatment.

At present, the methods used for restenosis include: simple balloon re-expansion, directional atherectomy, rotational atherectomy, intravascular radiotherapy and repeated stent implantation, etc. Existing bare balloon and drug stents exist Certain limitations, the restenosis rate of the bare balloon is relatively high, and the therapeutic effect of the drug stent on small vessels and bifurcated vessels is not good, neither of which has shown its ideal effectiveness or safety

Images